STOCK TITAN

Allarity expects stenoparib patent coverage into 2045

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. (ALLR) announced that the USPTO had granted a U.S. patent covering stenoparib treatment regimens. Its 36 allowed claims cover twice-daily oral administration, specified doses and schedules, and treatment methods for ovarian and other solid tumors. The release says the patent is expected to provide protection into 2045, while also listing issuance as scheduled for November 24, 2026.

Allarity said the regimen is used in its ongoing Phase 2 program and is intended to advance to pivotal trials. The new patent complements an earlier U.S. patent covering the company’s stenoparib-specific Drug Response Predictor companion diagnostic; the ovarian cancer Phase 2 protocol has been amended to add two patient groups for separate evaluation.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Allowed patent claims 36 claims Cover stenoparib dosing regimens and cancer-treatment methods
Expected patent protection Into 2045 The release says the patent is expected to provide protection into 2045
twice-daily oral administration medical
"claims cover twice-daily oral administration of stenoparib"
Drug Response Predictor technical
"stenoparib-specific Drug Response Predictor companion diagnostic"
PARP inhibitors medical
"including other PARP inhibitors"
PARP inhibitors are a class of cancer drugs that block an enzyme cells use to repair damaged DNA, effectively preventing cancer cells from fixing themselves and causing them to die. Investors watch them because their clinical approvals, safety profiles, patent status, and tests that identify which patients will benefit determine market size and revenue potential—much like backing a tool that only works on certain problems but can be very valuable when it does.
platinum-resistant medical
"patients with platinum-resistant or platinum-ineligible ovarian cancer"
Platinum-resistant describes a cancer that no longer responds to chemotherapy drugs containing platinum, such as cisplatin or carboplatin. Like a key that no longer fits a lock, these tumors stop shrinking after treatment, which matters to investors because it narrows standard therapy options, drives demand for novel drugs or combination regimens, affects clinical trial design and endpoints, and can change a treatment’s potential market size and regulatory path.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cancers are included in ALLR’s new stenoparib patent claims?

Allarity says the claims cover treatment methods for advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers. They also encompass patients whose disease has not responded to prior therapies, including other PARP inhibitors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001860657 0001860657 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 18, 2026

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41160   87-2147982
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On November 18, 2026, the Company issued a press release announcing that the United States Patent and Trademark Office had granted a U.S. patent covering certain stenoparib treatment regimens. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
  Description
99.1   Press Release, dated November 18, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
     
Date: November 19, 2026 By: /s/ Thomas H. Jensen
    Thomas H. Jensen
Chief Executive Officer

 

2

 

Exhibit 99.1

 

 

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

 

Patent with 36 allowed claims covering twice-daily treatment in ovarian cancer and other solid tumors

 

Strengthens intellectual property supporting the dosing strategy used in the Company’s ongoing Phase 2 program

 

TARPON SPRINGS, Fla., November 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the United States Patent and Trademark Office (“USPTO”) has granted a U.S. patent covering stenoparib treatment regimens. The patent is to provide protection for the claimed methods into 2045.

 

The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity’s clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

 

“The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval”.

 

The patent complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Together, these patents enable the Company’s strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

 

The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.

 

Allarity Therapeutics, Inc.   |  123 E Tarpon Ave  |  Tarpon Springs, Florida   |   U.S.A.  |  NASDAQ: ALLR   |   www.allarity.com

 

Page 1 of 4

 

 

 

About Allarity Therapeutics

 

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

 

About Stenoparib/2X-121

 

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

 

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

Under an earlier Phase 2 protocol evaluating stenoparib in patients with advanced ovarian cancer, Allarity observed promising and durable clinical benefit in patients who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from this earlier protocol were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

 

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol that began enrolling patients with platinum-resistant or platinum-ineligible ovarian cancer in the summer of 2025. Allarity has amended the protocol to add two patient groups that will be evaluated separately from the initial cohort enrolled under that protocol, namely patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”). The study is designed to advance the clinical development of stenoparib toward potential FDA approval.

 

Allarity Therapeutics, Inc.   |  123 E Tarpon Ave  |  Tarpon Springs, Florida   |   U.S.A.  |  NASDAQ: ALLR   |   www.allarity.com

 

Page 2 of 4

 

 

 

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

 

About the Drug Response Predictor – DRP® Companion Diagnostic

 

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

 

The DRP methodology is based on comparisons of sensitive and resistant human cancer cell lines and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

 

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

 

Follow Allarity on Social Media

 

LinkedIn: https://www.linkedin.com/company/allaritytx/

 

Allarity Therapeutics, Inc.   |  123 E Tarpon Ave  |  Tarpon Springs, Florida   |   U.S.A.  |  NASDAQ: ALLR   |   www.allarity.com

 

Page 3 of 4

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the scheduled issuance on November 24, 2026, the expected patent term extending into 2045, and the scope, validity, enforceability and commercial value of U.S. Patent No. 12,806,205; the ability of the patent claims to protect methods of treating cancer with stenoparib, including dosing regimens relevant to advanced ovarian cancer; the anticipated contribution of the patent to the Company’s intellectual property and commercial strategy; and the Company’s plans and ability to advance stenoparib toward late-stage development, regulatory approval and commercialization. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the patent issuance process, including potential delays or changes before grant; the scope, validity, enforceability, maintenance and interpretation of the patent; potential third-party challenges or other actions affecting the Company’s intellectual property rights; the Company’s ability to obtain, maintain and enforce intellectual property protection; the ability of stenoparib to demonstrate sufficient safety, efficacy, tolerability or clinical benefit to support further development or regulatory approval; the Company’s ability to conduct, enroll and complete ongoing and future clinical trials; the possibility that prior clinical observations may not be confirmed in ongoing or future studies; and the Company’s ability to secure sufficient financial, operational, manufacturing and clinical resources to continue development of stenoparib. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

 

###

 

Company Contact:
  investorrelations@allarity.com
   
Media Contact:
  Thomas Pedersen
  Carrotize PR & Communications
  +45 6062 9390
  tsp@carrotize.com

 

Allarity Therapeutics, Inc.   |  123 E Tarpon Ave  |  Tarpon Springs, Florida   |   U.S.A.  |  NASDAQ: ALLR   |   www.allarity.com

 

Page 4 of 4

Filing Exhibits & Attachments

4 documents

Keep reading